Kingworld Medicines Group Ltd 2024 SR

The report highlights Kingworld Medicines Group's commitment to the pharmaceutical and healthcare industry, focusing on supply chain management and sustainable development. In 2024, the company achieved a 3% reduction in non-hazardous solid waste and a 2.9% reduction in hazardous waste at its Dong Di Xin subsidiary. The Group actively managed climate risks through emergency plans for typhoons and floods. Socially, the company maintained a workforce of 972 employees with a 51.9% female ratio and invested approximately RMB 8.44 million in charitable donations, including disaster relief and educational support.

Company: Kingworld Medicines Group Ltd

Sector: Health Care

Country: China

Year: 2024

Type: SR

Pages: 44

Back to company

Kingworld Medicines Group Ltd

Kingworld Medicines Group Ltd 2024 ESG Report

ESG Report

The report highlights Kingworld Medicines Group's commitment to the pharmaceutical and healthcare industry, focusing on supply chain management and sustainable development. In 2024, the company achieved a 3% reduction in non-hazardous solid waste and a 2.9% reduction in hazardous waste at its Dong Di Xin subsidiary. The Group actively managed climate risks through emergency plans for typhoons and floods. Socially, the company maintained a workforce of 972 employees with a 51.9% female ratio and invested approximately RMB 8.44 million in charitable donations, including disaster relief and educational support.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2024

Reporting Period

Jan 1, 2024 - Dec 31, 2024

Fiscal Year

2024

Type

Sustainability Report

Language

English

Pages

 

File Size

 

Standards & Assurance

Materiality Assessment

Other Standards

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 2:

Energy Consumption

Water Consumption

Total Waste

Workplace Fatalities

Employees